XXXX : quality of life 30 months after treatment.

@entity1 @entity2653 @entity9144 @entity16 @entity3777 @entity1295 @entity158
OBJECTIVES: The prognosis after @entity9144 ( @entity9144 ) is debated. The aim of this study was to assess health-related Quality of Life (QoL) and @entity16 30 months after treatment in European @entity1 with @entity9144 . MATERIALS AND METHODS: In a prospective case-control designed study, we investigated 50 well-characterized @entity1 with @entity9144 who had participated in a treatment trial for @entity9144 30 months earlier and 50 matched control @entity1 with the health QoL questionnaire Short-Form 36 (SF-36), the @entity3777 ( @entity3777 ), the Montgomery and   sberg Depression Rating Scale (MADRS), the @entity2653 ( @entity2653 ), and the Mini Mental State (MMS). Clinical and demographic data were collected by semi-structured interviews and clinical neurological examination. RESULTS: @entity9144 -treated @entity1 scored lower than control @entity1 in the SF-36 domains physical component summary (PCS) (44 vs 51 P < 0.001) and mental component summary (MCS) (49 vs 54 P = 0.010). They also scored lower than control @entity1 in all the SF-36 subscales, except for @entity158 , and on @entity3777 (3.5 vs 2.1 P < 0.001), but not on MMS (28 vs 29 P = 0.106). There was a difference in MADRS (3.1 vs 0. 8 P = 0.003) and @entity2653 (13 vs 11 P = 0.016), but the scores were low in both groups. Fatigue was the most frequently reported symptom among @entity9144 -treated @entity1 (50%). @entity1 who reported complete recovery (56%) after @entity9144 had similar QoL scores as the controls. CONCLUSION: European @entity1 treated for @entity9144 have poorer health-related QoL and have more @entity1295 than @entity1 without @entity9144 .
